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PreviewsFrom Microbes to Prions:
The Final Proof of the Prion
Hypothesis
Much like the “microbe hypothesis” put forth over
150 years ago, the “prion hypothesis” can be defi-
nitely proven only if a prion disease is engendered in
a natural host from an infectious prion produced
in vitro. In this issue of Cell, Castilla et al. (2005) come
very close to accomplishing this goal by producing a
prion disease in a natural host from a prion entirely
generated in vitro using a PCR-like amplification
system.
In his 1840 publication On Miasmata and Contagia, Jo-
seph Henle put forward the hypothesis that infectious
diseases are caused by contagia animata (we now call
them microbes) and not by so-called miasma, an unde-
fined element that poisoned the air (Magner, 1992).
Henle’s publication, ignored for many years, received
landmark status when the “microbe hypothesis” be-
came accepted (Magner, 1992). By that time, a set of
criteria known as “Koch’s postulates” had to be satis-
fied to prove the microbe hypothesis. The original dis-
ease had to be reproduced from microbes that were
cultured and purified in vitro, after being obtained from
the infected individual.
History is repeating itself with prions.
Prion diseases or transmissible spongiform encepha-
lopathies affect humans and animals. Although prion
diseases have an incidence of only one case per mil-
lion, they pose a considerable threat to public health
because, unlike neurodegenerative diseases, they are
transmissible not only between humans but also to hu-
mans from animals where they are endemic in several
species. The lack of inflammatory reaction characteris-
tic of infectious diseases, the long incubation time, and
the resistance of the infectivity to radiation that de-
stroys living microorganisms clearly set prion diseases
apart from other infectious diseases. These factors led
to the hypothesis that the infectious agent of these dis-
eases, later called prion, was not a living organism but
a protein (Griffith, 1967; Prusiner, 1982).
The identification of the infectious protein designated
scrapie prion protein (PrPSc) followed by the surprising
discovery that PrPSc had the same amino acid se-
quence as a normal host protein (PrPC) led to the “prion
hypothesis”: PrPSc is derived from PrPC via a post-
translational modification involving a conformational
transition of the α-helical structure in PrPC to β sheet
structures in PrPSc (Figure 1). Following this noncova-
lent structural conversion, PrPSc becomes aggregated,
insoluble in nondenaturing detergents, resistant to pro-
teases, and infectious (i.e., can convert endogenous
PrPC to the PrPSc isoform in a host). The prion hypothe-
sis, much like Henle’s microbe hypothesis, was re-
ceived with skepticism or even scorn. Even now, de-
spite the overwhelming evidence supporting it, somemaintain that the infectious agent must be a virus or a
virino (agent containing its own nucleic acid enveloped
in host-encoded protein) or that PrPSc must contain a
small amount of host-derived nucleic acid (the “co-
prion,” or molecule that specifies prion infectivity).
These alternative theories are maintained even though,
as with the miasma, no one has ever demonstrated the
presence of these agents. It is demanded that the prion
hypothesis satisfy the prion version of the Koch’s pos-
tulate: the original disease must be reproduced in a
recipient from prions grown and purified in vitro after
being obtained from an infected donor.
These criteria have been satisfied in yeast where pro-
teins that behave much like the mammalian prion pro-
tein have been identified. Recombinant prion-like yeast
proteins, rich in β structures acquired in vitro, stably
infected normal yeast cells and propagated the diverse
features of the artificially created prions (Tanaka et al.,
2004).
The closest proof of the prion hypothesis in mam-
mals is the recent demonstration that a recombinant,
truncated fragment of mouse PrPC can misfold in vitro
into β sheet-rich fibrils and cause a prion disease after
intracerebral inoculation (Legname et al., 2004). How-
ever, a major caveat of this remarkable work is that the
disease could only be engendered in transgenic mice
overexpressing the truncated PrP at 16 times the nor-
mal level of PrPC and only after a long incubation time.
Thus, several investigators have questioned whether
the in vitro-generated PrP fragment is indeed “infec-
tious” or simply acts by precipitating an existing condi-
tion that is already programmed genetically.
In this issue of Cell, Castilla and coworkers took a
different approach in an attempt to provide incontro-
vertible proof of the prion hypothesis. These investi-
gators had previously improved the efficiency of an
in vitro PrPC to PrPSc conversion system, originally in-
troduced by Caughey and collaborators (Kocisko et al.,
1994). A fundamental problem with the Caughey in vitro
conversion method is that the newly formed PrPSc re-
mains below the level of the template PrPSc and cannot
be proven to be infectious. A simple but critical feature
in the improved procedure is the addition of a sonica-
tion step between cycles of PrPC to PrPSc conversion
(Saborio et al., 2001).
The sonication cycles likely fragment the newly
formed PrPSc aggregates that, according to the “seed-
ing” model of PrPSc formation (Figure 1), serve as new
nucleation sites for PrPC to PrPSc conversion (Figure 2).
The procedure, designated as PMCA (for protein mis-
folding cyclic amplification), results in significant PrPSc
amplification, in a way reminiscent of PCR (Figure 2).
Castilla et al. have now further improved their PMCA
system, and they report that they can amplify newly
formed PrPSc through a theoretically infinite number of
cycles (Figure 2). Taking advantage of this property,
they diluted out the native PrPSc used in the initial con-
version cycles, which was isolated from an infected
hamster, and obtained a preparation that contains
PrPSc entirely generated in vitro. Needless to say, the
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156Figure 1. Refolding and Seeding Models of
PrPC to PrPSc Conversion
(A) The “refolding” model contends that a
high energy barrier prevents spontaneous
conversion of PrPC (green) to PrPSc (red), but
PrPC is in equilibrium with the conformation-
ally intermediate form PrP* (orange). PrP*
can bind to PrPSc via a currently uncharac-
terized factor referred to as protein X (yellow
box). This heterodimer reverts to PrP homo-
dimer and forms large aggregates. Protein X
is recycled while PrPSc monomers or oligo-
mers break off from the PrPSc aggregates
and form new heterodimers maintaining the
autocatalytic process.
(B) According to the “seeding” model, PrPC
and PrPSc are in reversible thermodynamic
equilibrium. When several monomeric PrPSc
molecules form a highly ordered nucleus,
PrPC can be rapidly recruited into the PrPSc
nucleus.for amplification. r
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Figure 2. Prion Propagation In Vitro by PMCA and Detection of the C
Infectivity of the In Vitro-Generated Prions by Inoculation to
Hamster
The conversion solution containing an excess of PrPC (green cir-
Scles) over the PrPSc seed (orange polygons) is subjected to multiple
cycles of conversion and sonication/incubation. Such a system can
replicate prion infinitely and efficiently in vitro. PrPSc aggregates C
igrow by recruiting (incubation) and converting PrPC into newly
formed PrPSc, while in the sonication/incubation phase, PrPSc ag- G
gregates are fragmented into smaller aggregates (new seeds). This
Jrestarts the cycle overcoming the rate-limiting process of the
in vitro PrP conversion associated with the original method. Gray K
Gboxes represent tubes.in vitro-generated PrPSc has all the chemical and physi-
pcal features of the original 263K prion used as the initial
template. More importantly, the in vitro-formed PrPSc f
pcaused a prion disease upon intracerebral inoculation
of wild-type hamsters phenotypically similar to that i
acaused by the 263K prion strain used as the templateAlthough the study of Castilla et al. makes significant
rogress toward proving the prion hypothesis, it still
alls a bit short of achieving this goal. For example, the
ossibility remains that RNA or other molecules present
n the original brain preparation might be amplified
long with PrPSc and might play a critical role in confer-
ing infectivity and specificity to the new PrPSc. This
otwithstanding, the PMCA system offers golden op-
ortunities to further investigate PrPC to PrPSc conver-
ion. It already indicates that the seeding mechanism
Jarrett and Lansbury, 1993) is more likely to be opera-
ional in PrPC to PrPSc conversion than the “refolding”
echanism (Griffith, 1967; Prusiner, 1991) (Figure 1).
he robustness of the PMCA system provides the op-
ortunity to study conversion analytically and mecha-
istically, for example by starting from a recombinant
rion and testing individually the molecules that may
e required for an efficient conversion. This is likely to
e accomplished in the near future.
The prion hypothesis will then be finally and irrefut-
bly proven, and, in a few years, we may look at it in
he same way we now look at the contagia animata
ypothesis, wondering how something so obvious
ould elicit so much controversy.
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